Haemonetics completed the acquisition of Vivasure Medical for €185m.

Haemonetics, a global medical technology company, completed the acquisition of Vivasure Medical, a medical technology company developing absorbable vascular closure devices, for €185m. “We’re extremely proud of the progress made in advancing closure technology, and grateful to the clinicians who supported Vivasure’s mission. Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide," Andrew Glass, Vivasure Medical CEO.